NBRV Key Statistics, Chart & Performance
The current stock price of NBRV is 1.42 USD. In the past month the price decreased by -5.96%. In the past year, price decreased by -69.25%.
NBRV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About NBRV
Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Company Info
NABRIVA THERAPEUTICS PLC
Alexandra House Office 225/227,, The Sweepstakes,, Ballsbridge
DUBLIN 19406 IE
CEO: Theodore Schroeder
Employees: 39
Phone: 3536108166640.0
NABRIVA THERAPEUTICS PLC / NBRV FAQ
What does NBRV do?
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Can you provide the latest stock price for NABRIVA THERAPEUTICS PLC?
The current stock price of NBRV is 1.42 USD.
Does NABRIVA THERAPEUTICS PLC pay dividends?
NBRV does not pay a dividend.
What is the ChartMill rating of NABRIVA THERAPEUTICS PLC stock?
NBRV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about NABRIVA THERAPEUTICS PLC (NBRV) stock?
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
What is the Price/Earnings (PE) ratio of NABRIVA THERAPEUTICS PLC (NBRV)?
NABRIVA THERAPEUTICS PLC (NBRV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.63).
NBRV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBRV. When comparing the yearly performance of all stocks, NBRV is a bad performer in the overall market: 92.64% of all stocks are doing better.
NBRV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NBRV. NBRV may be in some trouble as it scores bad on both profitability and health.
NBRV Financial Highlights
Over the last trailing twelve months NBRV reported a non-GAAP Earnings per Share(EPS) of -18.63. The EPS increased by 20.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NBRV Forecast & Estimates
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
For the next year, analysts expect an EPS growth of 49.57% and a revenue growth 89.23% for NBRV